CTO Abhimanyu Verma Sells Shares of SOPHiA GENETICS

Abhimanyu Verma, the Chief Technology Officer of SOPHiA GENETICS SA, sold 6,944 shares of the company on June 25, 2026. The shares were sold at an average price of $5.51 each, totaling $38,261.44. This transaction was planned, as indicated by the Rule 10b5-1 plan.

Insider Buying and Selling at SOPHiA GENETICS SA

Several insiders at SOPHiA GENETICS have been active in the market recently. Alongside Abhimanyu Verma, Philippe Menu, the Chief Medical Officer, sold 5,000 shares at $5.50 each on the same day. Earlier, on June 22, both Ross Muken, the President, and George Cardoza, the Chief Financial Officer, executed planned sales of 422 and 774 shares, respectively, at $5.38 each. Meanwhile, on June 18, insiders Vincent Ossipow and Jean-Michel Cossery purchased 19,724 and 28,818 shares respectively, without a pre-planned sale.

SOPHiA GENETICS SA Stock Down 29.4%

On Saturday, shares of NasdaqGS:SOPH traded near $5.75. SOPHiA GENETICS has a market cap around $482.4 million. The company, which isn't currently profitable, has a forward P/E ratio that isn't meaningful. The stock's 52-week range is between $2.81 and $5.94, with a 50-day moving average of $5.07 and a 200-day moving average of $4.72. The company's beta is 0.985, indicating moderate volatility.

Analysts Set New Price Targets

Analysts continue to show confidence in SOPHiA GENETICS. On June 15, 2026, BTIG reiterated its buy rating with a price target of $8. Guggenheim has also maintained a buy rating with a $7 target as of January 26, 2026. The consensus among analysts is a strong buy, with a mean price target of $8 across three opinions.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It provides a cloud-native software platform, SOPHiA DDM, used for analyzing and generating insights from multimodal data sets. The platform is utilized by hospitals, laboratories, and biopharmaceutical companies across Europe, North America, and the Asia-Pacific region. Founded in 2011, the company employs 415 people and is led by CEO George A. Cardoza.

Bottom Line

Insider transactions like those by Abhimanyu Verma offer a glimpse into the internal dynamics at SOPHiA GENETICS. These sales, part of planned transactions, don't necessarily indicate a lack of confidence. Investors often monitor such activities for insight into company performance. Keep in mind that these transactions are disclosed after the fact and should be considered as part of a broader investment analysis.